J vaccine
Johnson
“We expect the majority in Brazil because it is the largest country and also the maximum affected by the pandemic, so we expect many others to volunteer, but we also expect the best numbers in Colombia and Argentina.”The company’s goal is to prioritize countries that contribute to vaccine progression and will involve patients in trials, yes,” he added in an interview with Reuters on Thursday.
Read also: COVID-19 Pandemic: Sanofi, GSK Start-Up Trial for a Protein Vaccine
J vaccine
Your international trials will come with 60, 000 volunteers. All Latin American countries have the highest number of infections, making them exciting verification sites for vaccine developers, as it is to download reliable verification effects in spaces with the highest rates of active transmission and infection.
Read also: Safe Russian COVID-19 vaccine produces immune response: Lancet
Bacaltchuk said the resolution to publish the trials greatly led to the challenge of ensuring that a sufficient number of volunteers in a populated domain through other pharmaceutical corporations conduct tests of their own prototypes.”I think it’s a forward-looking threat and that’s why we move to a number of centers higher than other corporations to cover geographic spaces that aren’t covered by other studies,” he said.
He said the reaction of volunteers in the region has been “pretty positive” and he hopes it will continue.”This has an effect on everyone and will continue to have an effect even after the end, the consequences will continue, so we will have to review it to prevent it as soon as possible,” he said.
Read also: COVID-19 Vaccine: Health Officials Say USBut it’s not the first time Not ready for mass vaccines
Speak now